Compare CIB & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIB | PODD |
|---|---|---|
| Founded | 1945 | 2000 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 17.0B |
| IPO Year | 2025 | 2007 |
| Metric | CIB | PODD |
|---|---|---|
| Price | $67.33 | $160.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 21 |
| Target Price | $70.25 | ★ $341.48 |
| AVG Volume (30 Days) | 258.6K | ★ 763.3K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $56.74 | $24.55 |
| Revenue Next Year | $8.05 | $19.18 |
| P/E Ratio | ★ $10.87 | $52.54 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $40.00 | $182.25 |
| 52 Week High | $86.31 | $354.88 |
| Indicator | CIB | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 13.91 |
| Support Level | $61.43 | N/A |
| Resistance Level | $70.78 | $205.95 |
| Average True Range (ATR) | 2.34 | 6.67 |
| MACD | -0.89 | -1.78 |
| Stochastic Oscillator | 7.62 | 5.49 |
Grupo Cibest SA formerly BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala. The Bank has the following segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking and All other segments. The majority of revenue is generated from the Banking Colombia segment.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.